In late March, tumor markers "OnkoIFA-REA" and "OnkoIFA-CA 19-9" production "Alcor Bio" — a designer and manufacturer of reagents for laboratory diagnostics — successfully registered with the Federal Service on Surveillance in Healthcare and Social Development, said in a statement company.
Currently in clinical practice, a few dozens of different tumor markers: for the diagnosis of cancer (in combination with other diagnostic methods), for prognosis of cancer, and for monitoring the effectiveness of the therapy, for early detection of recurrence (before clinical manifestations). The results of laboratory tests for tumor markers, doctors use only in combination with other methods of diagnosis of cancer.
Reagent Kit "OnkoIFA — CEA" is intended for the quantitative determination of carcinoembryonic antigen (CEA) in human serum by enzyme-linked immunosorbent assay. CEA is the most commonly used marker for detection of cancer of the gastrointestinal tract. Detection of CEA is primarily associated with cancer of the colon and rectum, however, ¬ WIDE other malignant neoplasms (tumors of the breast, lung, pancreas, ovaries and other organs) may also lead to an increase in its concentration. There are a number of benign conditions in which the concentration of CEA significantly higher than normal, in particular, inflammatory lung and gastrointestinal tract, and benign tumors of the liver.
Reagent "OnkoIFA-CA 19-9" is intended for the quantitative determination of the concentration of cancer antigen CA 19-9 in human serum by ELISA. The increased concentration of CA 19-9 in the blood serum is frequently observed in patients with malignant tumors of the gastrointestinal tract, particularly carcinomas of the pancreas, colon, stomach and liver.
Increasing the concentration of CA 19-9, along with the increasing concentration of CEA suggests the pathology of the gall bladder. Detection of tumor-specific antigens may also be due to some other tumors. Determination of the concentration of CA 19-9 serum levels may be used for monitoring patients are diagnosed above ¬ mentioned tumors.
Both sets feature the most extensive range of detectable concentrations, high sensitivity and specificity; expanded borders hook effect of high concentrations, the presence of a set of control sera. Today, "Alcor Bio" offers professionals diagnostic laboratories the most popular tumor markers in clinical practice.